Some violations of kidney function in patients chronic obstructive pulmonary disease

T Ospanova; O Bilchenko; E Avdeeva; E Bolokadze; O Veremeenko

Автор(и)

T Ospanova Kharkov National Medical University,
O Bilchenko Kharkov National Medical University,
E Avdeeva Kharkov National Medical University,
E Bolokadze Kharkov National Medical University,
O Veremeenko Kharkov National Medical University,

Ключові слова:

kidney, microalbuminuria, chronic obstructive pulmonary disease, pulmonary function tests.

Анотація

The paper describes the development of pathological processes in the kidney in COPD patients. So, we have investigated indicators MAU, pulmonary function tests, lipid spectrum in patients with COPD, depending on the severity of disease. Highlighted the main pathogenetic factors of the development and progression of renal pathology in COPD.

Посилання

Ivanova D.A. Kardiorenalnie vzaimootnoshenia u olnuch serdechnoy nedostatochnostu s soputstvuyschey hronicheskoy obstructivnoy boleznu legkix. / [Article ussian] [Text]/ D.A. Ivanova, O.E. Soporova, M.E.

Stachenko // Bulleten Volgogradskogo nauchnogo centra RAMN. – 2008. - №1. – С.45-47.

Аvdeev S.N. Chronicheskoe obstructivnoe abolevanie legkix kak sistemnaya bolrzn / [Article in Russian] [Text]/ S.N. Аvdeev // Pulmonologita. – 2007. – N2. – С. 104-116

Stanford R. H. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals / Stanford R. H., Shen Y., McLaughlin T. Treat Respir Med. −2006.−Т.5.−Р. 343–349.

Eckardt K.U. Berahat W.M. Wiedmann A. et al. Role of hypoxy in the pathogenesis of renal disease // Kidney int. – 2005. – Vol. 99[Sup.]. – P. 46-51.

Volpe M. Microalbuminuria Screening in Patients With Hypertension: Recommendations for Clinical Practice. // Int J Clin Pract. – 2008. - 62 (1): 97-108

Barnes P.J. Stockley R.A. Current therapeutic interventions and future approaches // Eur. Respir. J. – 2005. – Vol. 25. – P. 1084-1106.

Holdaas H. Fellsrow B. Jardine A.G. et al. Effect of fluvastatin on cardiocontcones in renal transplant recipients: a multi centre, randomized, placebo controlled trial // Lancet. – 2003. – Vol. 361. – P. 2024 031.

Veeramachaneni S.B., Sethi S. Pathogenesis of bacterial exacerbations of COPD. // COPD − 2006. − №3. − Р. 109–115.

Celli B. R., Barnes P. J. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease // Eur Respir J. −2007.−Vol.29.− P. 1224–1238.

Calverley P., Pauwels R., Vestbo J. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial // Lancet.− 2003.− Vol. 361. − P. 449–456.

Burge P.S., Calverley P.M.A., Jones P.W. et al. 2000) Randomised, double-blind, placebo controlled study of fluticasone ropianate in patients with moderate to severe chronic obstructive isease: the ISOLDE trial. //

B. M. J., 320: 1297-1303.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO workshop report, NIH

publication. Updated July, 2003

Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. PS Burge, PMА Calverley, PW Jones et all. //BMJ - 2000;320: Р. 1297-1303.